Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Zhu, Weiwei [2 ]
Wang, Rong [3 ,4 ]
Stahl, Maximilian [1 ,2 ]
Huntington, Scott F. [3 ,5 ]
Giri, Smith [3 ,6 ]
Podoltsev, Nikolai A. [1 ,2 ]
Gore, Steven D. [1 ,3 ]
Ma, Xiaomei [2 ,4 ]
Davidoff, Amy J. [3 ,7 ]
机构：
[1] Yale Sch Med, Sect Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[3] Yale Univ, Sch Med, Yale Canc Outcomes Publ Policy & Effectiveness Re, New Haven, CT USA
[4] Yale Univ, Yale Sch Publ Hlth, Dept Chron Dis, New Haven, CT USA
[5] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA
[6] Yale Univ, Sch Med, Sect Hematol, New Haven, CT USA
[7] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
838
引用
收藏
页数：3
相关论文
共 49 条
  • [1] Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)
    Coughlan, Anna
    Klijn, Sven L.
    Xiao, Hong
    White, Benjamin
    Litkiewicz, Michal
    Kadambi, Ananth
    Sichevaya, Alina
    Hnoosh, Ahmed
    Miteva, Dimana
    Yucel, Aylin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S351 - S351
  • [2] Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
    Santini, Valeria
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Savona, Michael Robert
    Fenaux, Pierre
    Madanat, Yazan F.
    Oliva, Esther
    Buckstein, Rena
    Jonasova, Anna
    Germing, Ulrich
    Mittelman, Moshe
    Thepot, Sylvain
    Riggs, Jennifer
    Dougherty, Souria
    Berry, Tymara
    Navada, Shyamala
    Xia, Qi
    Sun, Libo
    Zeidan, Amer M.
    Platzbecker, Uwe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S386 - S387
  • [3] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
    Platzbecker, Uwe
    Germing, Ulrich
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zhang, George
    Ha, Xianwei
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
  • [4] Hematologic and transfusion outcomes in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept: Real-world assessment in the community practice setting
    Mukherjee, Sudipto
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Makinde, Adeola Y.
    Bland, Emily
    Laney, JaLyna
    Garretson, Marne Prime
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
    Zeidan, Amer M.
    Zhu, Weiwei
    Stahl, Maximilian
    Wang, Rong
    Huntington, Scott F.
    Giri, Smith
    Podoltsev, Nikolai A.
    Gore, Steven D.
    Ma, Xiaomei
    Davidoff, Amy J.
    LEUKEMIA & LYMPHOMA, 2019, 60 (13) : 3181 - 3187
  • [6] Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Skikne, Barry
    Beach, C. L.
    Weaver, Jerry
    Tu, Nora
    Fenaux, Pierre
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1475 - 1483
  • [7] Longer-term RBC transfusion reduction in the phase 3 MEDALIST study of luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS)
    Platzbecker, U.
    Giagounidis, A.
    Heuser, M.
    Goetze, K.
    Thol, F.
    Fenaux, P.
    Komrokji, R. S.
    Laadem, A.
    Ito, R.
    Rampersad, A.
    Zhang, J.
    Louis, C. U.
    Germing, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 169 - 169
  • [8] Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
    Mittelman, Moshe
    Henry, David H.
    Glaspy, John
    Tombak, Anil
    Harrup, Rosemary Anne
    Madry, Krzysztof
    Grabowska, Barbara
    Platzbecker, Uwe
    Lee, Tyson
    Modelska, Katharina
    BLOOD, 2023, 142
  • [9] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
    Komrokji, Rami S.
    Santini, Valeria
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Berry, Tymara
    Sherman, Laurie
    Navada, Shyamala
    Feller, Faye M.
    Sun, Libo
    Xia, Qi
    Wan, Ying
    Huang, Fei
    Zeidan, Amer M.
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [10] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
12345